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We would like to thank Dr. Maraolo for his valuable and
careful analysis [1] of the data of our recently published sys-
tematic review and meta-analysis on probiotic and synbiotic
therapy in the critically ill [2]. As Dr. Maraolo has observed
we have made an error in the calculation of the pooled risk
ratio (RR) and 95% confidence interval (CI) for the effect of
probiotics on hospital mortality. When we abstracted mor-
tality data from the Besselink et al. [3] study we included
correct data in both arms (24 of 152 and 9 of 144 patients
in the probiotic and placebo groups, respectively). Nonethe-
less, we made a mistake creating the forest plot. Please,
accept our sincere apologies.
Currently, after including the correct data from the
Besselink et al. study using the random effect model
in the software RevMan 5.3 (Cochrane IMS, Oxford,
UK), we found that the revised effect of probiotics
and synbiotics therapy on overall mortality is 1.02
(95% CI 0.85,1.22; p = 0.83, I2 = 0%; Fig. 1). Notwith-
standing, at this point we respectfully disagree with
Dr. Maraolo. Certainly, after reassessing the RR this
new result does not change the direction of the effect
against the use of probiotics in the critically ill. Our
previous data showed that the RR was 0.98 with a CI
similar to the present one (0.85, 1.22). Moreover, the
p value was 0.83 and we cannot thus affirm that a
trend against probiotics on mortality exists, as we de-
fined trend with a p value <0.10. So far, clinical trials
evaluating the effects of probiotics (excluding Saccha-
romyces boulardii, which should not be considered as
a probiotic in the critical care setting) [4] in different
ICU patient populations have documented safety and
clinical benefits, as we recently demonstrated in our
systematic review.
Having said that, the conclusion of our meta-analysis re-
mains unchanged. According to our findings probiotic
therapy may be associated with a significant reduction in
overall new infections, including new episodes of
ventilator-associated pneumonia. However, no benefits in
terms of reduction in mortality or another relevant clinical
outcome for critically ill patients have been pointed out.
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Fig. 1 Effect of Probiotics and Synbiotics Therapy on Hospital Mortality
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